ONCY - Latest News
Oncolytics Biotech Inc. (ONCY), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $90.3M. Beta to the broader market is 1.03.
The article list below shows the most recent ONCY headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ONCY Headlines
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
globenewswire.com - Jun 1, 2026
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company develo
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors
globenewswire.com - May 22, 2026
Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor g
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks
benzinga.com - May 4, 2026
Oncolytics Biotech, Inc. (NASDAQ:ONCY) shares are up on Monday as the company reported promising durability data for its investigational immunotherap
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
globenewswire.com - May 4, 2026
2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Month Benchmark Company Engaged with FDA to Support
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
globenewswire.com - Apr 27, 2026
Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to foc
How News Affects ONCY Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ONCY's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ONCY news questions
- What is the latest ONCY news headline?
- The most recent ONCY headline (Jun 1, 2026) is "Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ONCY news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ONCY news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ONCY options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.